Whole-genome sequencing of samples from patients with myeloid malignancies can enable more accurate risk stratification than is possible with conventional cytogenetics. Research by Duncavage et al. demonstrates that such an approach can now be delivered within several days using a highly streamlined and automated workflow.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Byrd, J. C. et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461). Blood 100, 4325–4336 (2002).
Döhner, H. et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129, 424–447 (2017).
De Witte, T. et al. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: Recommendations from an international expert panel. Blood 129, 1753–1762 (2017).
Duncavage, E. J. et al. Genome Sequencing as an Alternative to Cytogenetic Analysis in Myeloid Cancers. N. Engl. J. Med. 384, 924–935 (2021).
Byrd, J. C. et al. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J. Clin. Oncol. 17, 3767–3775 (1999).
Welch, J. S. et al. TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes. N. Engl. J. Med. 375, 2023–2036 (2016).
DiNardo, C. D. et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133, 7–17 (2019).
Burd, A. et al. Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. Nat. Med. 26, 1852–1858 (2020).
Sekeres, M. A. et al. Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. Blood 113, 28–36 (2009).
Röllig, C. et al. Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia? Blood 136, 823–830 (2020).
Acknowledgements
This article is dedicated to Dr. Clara D Bloomfield who pioneered cytogenetics in AML and served as an exceptional mentor to us as well as many other active members in this field.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J.C.B. has received research support from Acerta Pharma, Genentech, Janssen Pharmaceutica, and Pharmacyclics and has served on the advisory boards of AstraZeneca, Novartis, Syndax Pharma and Trillium, and has substantial ownership interests in Vincerx Pharma. K.T.M.L declares no competing interests.
Rights and permissions
About this article
Cite this article
Larkin, K.T.M., Byrd, J.C. Whole-genome sequencing for myeloid disease: one assay to stratify them all?. Nat Rev Clin Oncol 18, 543–544 (2021). https://doi.org/10.1038/s41571-021-00522-z
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-021-00522-z
